Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients.
The authors report an intense downregulation of transforming growth factor-beta1 (TGF-beta1) serum levels 4 weeks from start of interferon-beta1a (IFN-beta1a) treatment at 44 microg/week in 271 patients with relapsing-remitting MS, which was still present after 1 year (p < 0.001). In line with previous data, interleukin-10 serum levels did not vary significantly. These results indicate that the immunomodulatory effects of IFN-beta might not be restricted to the postulated anti-inflammatory mechanisms and address the role of TGF-beta in the pathogenesis of MS.
Lünemann
J D
JD
Division of Neuroimmunology, Department of Neurology, Charité University Hospital, Berlin, Germany.
Aktas
O
O
Gniadek
P
P
Zschenderlein
R
R
Zipp
F
F
D000328:Adult; D000368:Aged; D004185:Disability Evaluation; D015536:Down-Regulation / Q000187:drug effects; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood / Q000188:drug therapy*; D009460:Neurologic Examination / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000097:blood*; D053773:Transforming Growth Factor beta1
C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a